Docetaxel and zoledronic acid combination administered in two different sequences in hormone refractory prostate cancer patients: Phase I clinical study – ZANTE

G. Facchini; M. Caraglia; A. Morabito; S.G. Bruni; G. Nasti; P. Maiolino; S. Striano; A. Budillon; A. Di Napoli; M. Marra; C. Pisano; S. Pignata; F. Perrone; R.V. Iaffaioli

doi:10.1016/j.ejcsup.2008.06.048

Docetaxel and zoledronic acid combination administered in two different sequences in hormone refractory prostate cancer patients: Phase I clinical study – ZANTE

By G. Facchini, M. Caraglia, A. Morabito, S.G. Bruni, G. Nasti, P. Maiolino, S. Striano, A. Budillon, A. Di Napoli, M. Marra, C. Pisano, S. Pignata, F. Perrone and R.V. Iaffaioli

Publisher: Elsevier BV

Year: 2008

DOI identifier: 10.1016/j.ejcsup.2008.06.048

OAI identifier:

Provided by: MUCC (Crossref)

Download PDF:
_{Sorry, we are unable to provide the full text but you may find it at the
following location(s):}

https://doi.org/10.1016/j.ejcs... (external link)

Docetaxel and zoledronic acid combination administered in two different sequences in hormone refractory prostate cancer patients: Phase I clinical study – ZANTE

Suggested articles